Schwann-like adipose-derived stem cells and nerve injury: Peripheral nerve injuries (PNIs) are a common clinical problem usually as a consequence of trauma. Despite optimal surgical management, PNI has a lifelong impact on function and wellbeing of the patient.

The peripheral nervous system (PNS) has regenerative capability, in contrast to the central nervous system (CNS), and is dependent on the plasticity of the peripheral glia, Schwann cells (SCs). Despite this regenerative capability, PNI recovery of sensorial and motor function is always incomplete causing pain, cold intolerance, paralysis and impairment of activities of daily living. Therefore, development of innovative approaches enhancing PNS regeneration after injury is of great clinical relevance (Faroni et al., 2015).

It is widely accepted that the current microsurgical approach in isolation to PNI is insufficient to address the complex cellular and molecular mechanisms occurring in the nerve injury environment; however, there are no available adjunctive therapies or pharmacological treatments that improve outcomes for patients. In addition, greater understanding of PNI and regeneration has demonstrated that timing of any intervention is fundamental for optimal recovery (De Stefano et al., 2013; Faroni et al., 2015).

Cell-based therapies for PNI have demonstrated experimental potential and appear to be a promising paradigm for clinical intervention towards improved functional outcomes, especially in the presence of a nerve gap. The use of SCs has been investigated with some experimental success; however, their clinical application is limited, due to the necessity of sacrifice of a functional healthy nerve and considering that SC harvest and amplification timescales are no available adjunctive therapies or pharmacological treatments that improve outcomes for patients. In addition, greater understanding of PNI and regeneration has demonstrated that timing of any intervention is fundamental for optimal recovery (De Stefano et al., 2013; Faroni et al., 2015).

Acetylcholine (ACh) and Schwann-like dASCs: Neurotransmitters are known pharmacological modulators of SC physiology and myelination (Loreti et al., 2006, 2007; Uggenti et al., 2014; Faroni et al., 2016, 2019). Exploration of neurotransmitter receptor manipulation to regulate dASC physiology has been demonstrated with GABA-B receptor ability to modulate BDNF and NGF secretion (Faroni, et al., 2013), whilst P2X7 receptor controls cell death (Faroni, et al., 2013). Recently, we have demonstrated that rat ASCs (Piovesana et al., 2018), dASCs (Piovesana et al., 2019) and native SCs (Loreti et al., 2006) all express muscarinic receptor subtypes, with a greater expression of M2 subtype. The presence of ACh in non-neuronal tissue has been largely established and via M2 subtype it is able to suspend ASC activity, reducing their cell growth and migration. After the removal of cholinergic stimulation, ASCs are able to rescue their proliferation, a necessary condition for the maintenance of stem cell self-renewal (Piovesana et al., 2018).

Following differentiation, M2 receptor activation in dASCs by orthosteric selective agonist arecaidine propargyl ester (APE), produces similar effects observed in SCs (Loreti et al., 2007; Uggenti et al., 2014). In particular, M2 receptors inhibit cell proliferation in a reversible manner and cell migration; moreover they assume a more pronounced spindle-shaped morphology with an upregulated expression of SC differentiation markers (i.e. Eg2/Krox20, myelin protein zero) (Piovesana et al., 2019). These data suggest that M2 receptor selective stimulation supports dASC phenotype promoting their differentiation (Additional Table 1) (Piovesana et al., 2019).

Muscarinic receptors and neurotrophic factor production: The first relevant aspect supporting neuronal survival and axon elongation after nerve injury is the local production of neurotrophic factors. Exogenous administration of neurotrophic factors or other small molecules and peptides have not proven successful experimentally, perhaps due to the very particular temporospatial control of native SCs in the neurotrophic production, but also due to interactions and potential side-effects which could impair axonal growth or significantly increase neuropathic pain (Faroni et al., 2015). Pharmacological stimulation of the resident cells to produce neurotrophic factors or transplantation of neurotrophic factor producing cells are a potential adjunct to address nerve regeneration.

Both ASCs and dASCs represent a rich source of neurotrophic growth factors. We have recently demonstrated that rat dASCs produce and release higher basal levels of proNGF and release higher concentration of mature NGF than SCs (Piovesana et al., 2020). Furthermore, we have determined for the first time that cholinergic stimulation regulates the production and secretion of NGF in both rat dASCs and SCs (Piovesana et al., 2020). The pharmacological modulation of all muscarinic receptors, using the non-selective agonist muscarine, as well as the selective activation of M2 receptor subtype, using APE treatment, regulate the production and secretion of NGF both in rat dASCs.
and SCs, and significantly downregulate the proNGF-B isofrom (25 kDa) expression, mainly involved in the apoptosis (Piovesana et al., 2020). The negative modulation of proNGF-B suggests an improvement of dASC and SC capability in reducing neuronal death (Additional Table 1).

Native SCs are highly productive of neurotrophic factors, although cholinergic stimulation increases NGF production even within 24 hours of M2 receptor stimulation (Piovesana et al., 2020). These findings represent the first evidence for the positive role of cholinergic receptors in the modulation of NGF expression and release in the PNS.

Muscarnic stimulation upregulates tissue plasminogen activator (tPA) activity both in dASCs and SCs, indicating that cholinergic stimulation may efficiently promote the proNGF cleavage and therefore the production of the active form of NGF (mature NGF; mNGF) (Piovesana et al., 2020). Interestingly dASCs produce higher extracellular levels of MMP9 than SCs, an enzyme required to rapidly degrade mNGF and restore the microenvironment homeostasis.

These results indicate that muscarinic challenge can promote an NGF-mediated neuro-reparative response by dASCs, with promise to improve neuronal survival and axon regeneration via negative modulation of proNGF-B in native glial cells but also in the transplanted cells.

We corroborated the idea that non-selective treatment activating all muscarinic receptor subtypes generates a balance of their effects on dASC phenotype and on NGF metabolism; however it is now evident, that muscarine and APE treatments show comparable effects, suggesting that M2 receptor may be the main subtype involved in NGF metabolism both in dASCs and SCs.

Altogether these data demonstrate that dASCs are efficient producers of NGF and that the muscarinic receptors promote NGF production and maturation. Therefore, our findings highlight a new pharmacological target that could be used to enhance dASC phenotype and increase a local release of NGF by dASCs that could reduce the well-known effects of mechanical allodynia caused by the injection of exogenous NGF.

Human ASCs can differentiate towards SC-like phenotype: Human adipose tissue is also enriched in resident ASCs, useful for regenerative medicine. Human ASCs are positive for the typical markers CD29, CD44, CD90, CD73, CD105, CD271 and negative for CD14, CD20 and CD45 (Tomita et al., 2013; Faroni et al., 2016). After isolation they are able to differentiate in the three specific mesodermal lineages in vitro, producing fat droplets as adipogenic differentiation, proteoglycans as chondrogenic differentiation and calcium deposits for osteogenic differentiation (Faroni et al., 2016). The protocol used in rat ASCs was reproduced in human ASCs, with a good percentage of SC-like cells (Tomita et al., 2013). After 3–5 days of growth factors exposure in this differentiation protocol, dASCs assume an elongated spindle-shaped morphology that is maintained during in vitro passage, increased cell proliferation and higher levels of neurotrophic factors (e.g. NGF, BDNF and GDNF) compared to ASCs (Faroni et al., 2016). However, whilst human dASCs have this regenerative potential, they require continuous chemical stimulation and trans-differentiation seems unlikely. Growth factor withdrawal following this differentiation protocol results in a reversion of dASC phenotype and significant reduction of growth factor expression to an undifferentiated state within 72 hours (Faroni et al., 2016). On the other hand, 8 weeks following human dASC cell transplantation in athymic nude rats show a small number of human cells associated with myelinated axons (Tomita et al., 2013), proposing that the in vivo environment (e.g., axon contacts, resident SCs or paracrine signals) could induce or change ASC characteristics and perhaps maintain dASC phenotype.

Further research on human cells is required to understand whether environmental factors or other molecules can stabilize the dASC phenotype in vitro and also in vivo. Here, we hypothesize that there may be a role for manipulation of muscarinic receptors to modulate the regenerative properties of ASCs and dASCs towards a clinically relevant intervention.

Future perspective and conclusions: In a regenerative scenario, our results propose dASCs as a remarkable cell population useful as substitution of SCs, considering their ability to create pro-regenerative environment by neurotrophic factor production. The data obtained in the rat model open the possibility that human dASCs may play a strategic role in the nerve regeneration; however, current ASC differentiation protocols require constant chemical stimulation with different growth factors (i.e. GGF-2, Fsk, PDGF, bFGF) and our previous data demonstrate that growth factor withdrawal results in reversion to ASC phenotype. Therefore, we seek to identify new pharmacological treatments to stabilize the phenotype and improve physiological activities, especially in the maintenance of neurotrophic factor production. Starting from the evidence that muscarinic stimulation promotes spindle-like morphology and the upregulated expression of differentiation markers in rat SCs and in dASCs, we hypothesize that M2 receptor stimulation may support human dASC phenotype also in absence of growth factors. In conclusion, our data suggest an exciting clinical paradigm of schwann-like ASCs with cholinergic stimulation mediated by muscarinic receptors that could be transplanted in appropriate scaffolds to enhance and accelerate the peripheral nerve regeneration (Figure 1B).

The present work was supported by Ateneo Sapienza Funds 2017 (RM11715C7F959CA4) to AMT and “Avvio Giovani” Project 2018 (AR1181643A0F81D) from Ateneo Sapienza to RP. RP fellowship was also supported by CIB 2018. AF and AJR are supported by the Hargreaves and Ball Trust, the Academy of Medical Sciences (AMS-SGCL7), and by Seed Corn Funding from the Rosetrees Trust and the Stoneygate Trust (M746).

The authors are very grateful to Paul Mellidi for the illustration in Figure 1B.

Robert Piovesana, Alessandro Faroni, Ada Maria Tata, Adam J. Reid* Department of Biology and Biotechnologies “Charles Darwin”, Sapienza, University of Rome, Rome, Italy (Piovesana R, Tata AM) Blond McIndoe Laboratories, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK (Piovesana R, Faroni A, Reid AJ) Research Centre of Neurobiology “Daniel Bovet”, Sapienza, University of Rome, Rome, Italy (Tata AM)

*Correspondence to: Adam J. Reid, MBChB, FRCS (Plast), PhD, Adam.Reid@manchester.ac.uk. https://orcid.org/0000-0003-1752-3302

Date of submission: June 18, 2020
Date of decision: July 28, 2020
Date of acceptance: September 19, 2020
Date of web publication: November 27, 2020
Summary of our results

ASCs                                                             dASCs                                                              SCs

| A | 1 mM β-mercaptoethanol for 24 hours |
|---|----------------------------------|
| B | 14 μM Fsk, 192 ng/mL GGF-2, 5 ng/mL bFGF (Peprotech, USA) for 14 days |
| C | 14 μM Fsk, 192 ng/mL GGF-2, 5 ng/mL bFGF (Peprotech, USA) for 14 days |
| D | 35 ng/mL all-trans-retinoic acid for 72 hours |

Figure 1 | ASC differentiation and potential clinical application. (A) ASC differentiation towards Schwann-like phenotype: For differentiation to SC phenotype, passage 1–2 ASCs were treated with stem cell growth medium supplemented with 1 mM β-mercaptoethanol for 24 hours. The next day, cells were incubated with 10 mL of pre-conditioning medium for 72 hours containing 35 ng/mL all-trans-retinoic acid (Sigma-Aldrich, UK) at 37°C. Following all-trans-retinoic acid treatment, cells were washed carefully and stem cell medium was replaced and supplemented with 14 μM forskolin (Sigma-Aldrich, UK), 192 ng/mL GGF-2 (Acorda, UK), 5 ng/mL bFGF (Peprotech, USA), and 10 ng/mL bFGF (Peprotech, USA) for 14 days. The same supplemented medium was used for cell maintenance. Figure A is sourced from the authors’ unpublished data. (B) Potential clinical application of human dASCs for the treatment of the peripheral nerve injury: challenges and future studies: Adipose tissue can be lipoaspirated from the nerve injured patient (a) and ASCs isolated (b). These cells are subsequently differentiated towards Schwann-like phenotype (dASCs) after 18 days of exposure to chemical factors (c). We propose that scaffolds augmented with pharmacological treatments of muscarinic mimetics (e.g. APE) could be used to deliver dASCs with subsequent increased neurotrophic factor production (f). An alternative route to the clinic might be the use of muscarinic mimetics to mitigate the reversion of human dASCs to previous ASC phenotype after growth factor withdrawal (a). Data obtained in rat ASCs demonstrate that APE intervention improves dASC phenotype; therefore muscarinic mimetics could support human dASC phenotype and neurotrophic factor production (f). APE: Arecaidine propargyl ester; ASC: adipose-derived stem cells; bFGF: basic fibroblast growth factor; dASCs: differentiated adipose-derived stem cells; GGF-2: glial growth factor-2; PDGF: platelet-derived growth factor; SCs: Schwann cells.

Additional file: 

Additional Table 1: Summary of our results obtained in rat dASCs, compared with untreated cells (Piovesana et al., 2019, 2020).

References

De Stefano ME, Toni F, Orazi VD, Orenti A, Tata AM (2013) Therapeutic approaches enhancing peripheral nerve regeneration. Adv Biosci Biotechnol 04:53-60.

Dezawa M, Takahashi I, Esaki M, Takano M, Sawada H (2001) Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. Eur J Neurosci 14:1771-1776.

Faroni A, Calabrese F, Riva MA, Terenghi G, Magnaghi V (2013) Baclofen modulates the expression and release of neurotrophins in Schwann-like adipose stem cells. J Mol Neurosci 49:233-243.

https://doi.org/10.4103/1673-5374.300433

How to cite this article: Piovesana R, Faroni A, Tata AM, Reid AJ (2021) Schwann-like adipose-derived stem cells as a promising therapeutic tool for peripheral nerve regeneration: effects of cholinergic stimulation. Neural Regen Res 16(6):1218-1220.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Table 1  Summary of our results obtained in rat dASCs, compared with untreated cells (Piovesana et al., 2019, 2020)

### M2 Activation

|                         |          |
|-------------------------|----------|
| **Morphology** (Piovesana et al., 2019) |          |
| Cell diameter           | ↓        |
| Aspect ratio            | ↑        |
| **Cell proliferation and SC differentiation** (Piovesana et al., 2019) |          |
| Cell growth             | ↓        |
| c-Jun                   | ↓        |
| Egr2                    | ↑        |
| Notch-1                 | ↓        |
| Nrg-1 type 1            | ↓        |
| Nrg-1 type 3            | ↑        |
| erbB2                   | ↑        |
| erbB3                   | ↑↓       |
| **Cell migration** (Piovesana et al., 2019) |          |
| Cell migration          | ↓        |
| CXCR4-7/CXCL12 pathway  | ↓        |
| **NGF system** (Piovesana et al., 2020) |          |
| NGF isoform A transcript| ↑        |
| Protein/Activity                  | Change |
|----------------------------------|--------|
| NGF isoform A protein            | ↓↑     |
| NGF isoform B transcript         | ↓      |
| NGF isoform B protein            | ↓      |
| P75NTR protein                   | ↑      |
| tPA activity                     | ↑      |